BLRX רווח למניה בשנים עשר החודשים האחרונים BioLineRx Corporation

Integration into global science and patent protection in the EU and US minimize geopolitical risks, which supports the price action of BioLineRx Ltd. (BLRX). The company's net profit per share over 12 months reflects the current status of -1.81. Growth is driven by Aphexda sales for hematology, the high authority of the Israeli brand in oncology, and the successful implementation of vital stem cell mobilization methods.

Earnings per share (EPS TTM) measures the portion of profit allocated to each ordinary share over a year. Positive momentum in this indicator confirms effective capital management amid high borrowing costs. By analyzing the rolling EPS snapshot, an investor determines the actual profitability of the business. For BioLineRx Ltd. (BLRX), this metric reflects the success of drug commercialization. Diversifying the drug portfolio reduces dependence on early-stage development risks.